Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
January 21, 2018
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry
Anthony Mato, Chadi Nabhan, Neil E Kay, et al.
British Journal of Haematology
|
June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones, Anthony Mato, Steven Coutre, et al.
British Journal of Haematology
|
December 16, 2016
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Tadeusz Robak, Andrzej Hellmann, Janusz Kloczko, et al.
Blood Advances
|
April 10, 2020
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites
Anthony Mato, Chadi Nabhan, Nicole Lamanna, et al.
British Journal of Haematology
|
November 19, 2016
Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres
Anthony Mato, Chadi Nabhan, Neil E Kay, et al.
Blood
|
June 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
John F Seymour, John C Byrd, Paolo Ghia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella, Saad S Kenderian, Olga Shestova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2020
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
Noelle V Frey, Saar Gill, Elizabeth O Hexner, et al.
Blood and Lymphatic Cancer : Targets and Therapy
|
September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Chaitra Ujjani, Anthony Mato, Brian T Hill, et al.
Haematologica
|
October 15, 2020
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration
Deborah M Stephens, Ken Boucher, Elizabeth Kander, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Clinical Lymphoma, Myeloma & Leukemia
|
January 21, 2018
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry
Anthony Mato, Chadi Nabhan, Neil E Kay, et al.
British Journal of Haematology
|
June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones, Anthony Mato, Steven Coutre, et al.
British Journal of Haematology
|
December 16, 2016
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Tadeusz Robak, Andrzej Hellmann, Janusz Kloczko, et al.
Blood Advances
|
April 10, 2020
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites
Anthony Mato, Chadi Nabhan, Nicole Lamanna, et al.
British Journal of Haematology
|
November 19, 2016
Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres
Anthony Mato, Chadi Nabhan, Neil E Kay, et al.
Blood
|
June 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
John F Seymour, John C Byrd, Paolo Ghia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella, Saad S Kenderian, Olga Shestova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2020
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
Noelle V Frey, Saar Gill, Elizabeth O Hexner, et al.
Blood and Lymphatic Cancer : Targets and Therapy
|
September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Chaitra Ujjani, Anthony Mato, Brian T Hill, et al.
Haematologica
|
October 15, 2020
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration
Deborah M Stephens, Ken Boucher, Elizabeth Kander, et al.
Page
of 7